Plausibly, ERα (+)/PgR(−)/HER2(+) BCs show inferior prognosis because they represent an end-point in the pathway beginning with early, occult dissemination initially driven by PgR(+) cells, while clinically overt PgR(−) cancers may comprise only of residual scattered phospho-PgR(+) spots with stem cell potential and an ability to spread [85]. The gene discussed is ERBB2; the disease is cancer.